Insulet (PODD) Stock Price
Insulet Price
Revenue has compounded at 41.6% per year over the past 19 years to 2.71 B USD. Earnings per share have grown at 81.5% per year over the last 7 years. Insulet's net margin stands at 9.1%, up from 1.5% several years earlier. Analysts set a median price target of 367.20 USD, implying 177.9% above the current price. Of 34 analysts, 30 rate the stock a buy — an overall Buy consensus.
Insulet stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Insulet over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Insulet stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Insulet's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Insulet Price |
|---|---|
| 9/11/2026 | 132.12 USD |
| 9/10/2026 | 134.68 USD |
| 9/9/2026 | 137.92 USD |
| 9/8/2026 | 140.76 USD |
| 9/4/2026 | 147.71 USD |
| 9/3/2026 | 150.58 USD |
| 9/2/2026 | 148.14 USD |
| 9/1/2026 | 148.38 USD |
| 8/31/2026 | 148.89 USD |
| 8/28/2026 | 146.04 USD |
| 8/27/2026 | 143.20 USD |
| 8/26/2026 | 143.38 USD |
| 8/25/2026 | 143.05 USD |
| 8/24/2026 | 146.82 USD |
| 8/21/2026 | 148.16 USD |
| 8/20/2026 | 146.87 USD |
| 8/19/2026 | 151.95 USD |
| 8/18/2026 | 146.32 USD |
| 8/14/2026 | 143.34 USD |
| 8/13/2026 | 146.44 USD |
| 8/12/2026 | 145.06 USD |
| 8/11/2026 | 144.70 USD |
| 8/10/2026 | 143.06 USD |
| 8/7/2026 | 141.17 USD |
| 8/6/2026 | 139.30 USD |
| 8/5/2026 | 132.05 USD |
| 8/4/2026 | 167.13 USD |
| 8/3/2026 | 169.70 USD |
| 7/31/2026 | 165.35 USD |
| 7/30/2026 | 165.68 USD |
Insulet Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Insulet Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.37 | 0.46 | 0.56 | 0.74 | 0.90 | 1.10 | 1.31 | 1.70 | 2.07 | 2.71 | 3.29 | 3.76 | 4.28 | 4.94 | 5.28 |
| -8.68 | 39.16 | 26.50 | 21.60 | 31.08 | 22.49 | 21.46 | 18.85 | 30.04 | 22.04 | 30.76 | 21.57 | 14.31 | 13.77 | 15.28 | 7.05 |
| 50.57 | 57.65 | 59.83 | 65.72 | 65.04 | 64.38 | 68.49 | 61.69 | 68.30 | 69.77 | 71.60 | 71.60 | 71.60 | 71.60 | 71.60 | 71.60 |
| 0.13 | 0.21 | 0.28 | 0.37 | 0.48 | 0.58 | 0.75 | 0.81 | 1.16 | 1.45 | 1.94 | 2.36 | 2.69 | 3.07 | 3.53 | 3.78 |
| -0.05 | -0.01 | -0.01 | 0.03 | 0.05 | 0.05 | 0.08 | 0.04 | 0.22 | 0.31 | 0.47 | 0.64 | 0.75 | 0.88 | 1.06 | 1.19 |
| -18.25 | -3.28 | -1.51 | 4.80 | 6.78 | 5.97 | 7.38 | 2.76 | 12.96 | 14.87 | 17.47 | 19.41 | 20.04 | 20.49 | 21.46 | 22.60 |
| -73.00 | -28.00 | -26.00 | 3.00 | 11.00 | 6.00 | 16.00 | 4.00 | 206.00 | 418.00 | 247.00 | 467.00 | 554.00 | 667.00 | 801.00 | 908.00 |
| 43.14 | -61.64 | -7.14 | -111.54 | 266.67 | -45.45 | 166.67 | -75.00 | 5,050.00 | 102.91 | -40.91 | 89.07 | 18.63 | 20.40 | 20.09 | 13.36 |
| 56.93 | 57.44 | 58.24 | 61.08 | 63.89 | 65.95 | 69.81 | 70.02 | 69.86 | 74.08 | 70.67 | 70.67 | 70.67 | 70.67 | 70.67 | 70.67 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Insulet generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Insulet retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Insulet's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Insulet has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Insulet's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Insulet stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Insulet Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Insulet business model & stock analysis
Insulet SWOT Analysis
Strengths
Insulet Corp has developed a highly innovative technology in the form of its tubeless insulin delivery system known as the Omnipod. This technology provides significant benefits to diabetic patients, such as increased convenience, freedom, and improved glycemic control. The Omnipod's unique design has positioned the company as a market leader in the insulin pump industry.
Insulet Corp has established a strong market presence, with its products being widely recognized and accepted within the healthcare industry. This has enabled the company to secure partnerships with major insurers and healthcare providers, further enhancing its market position and ensuring steady revenue streams.
Weaknesses
Insulet Corp heavily relies on the success of its Omnipod system, as it is the company's primary source of revenue. While the technology has proven to be highly effective, any potential issues or competition in the market could significantly impact Insulet Corp's financial performance. Diversification of product offerings may be necessary to mitigate this weakness.
Despite its strong market presence in certain regions, Insulet Corp's global reach is relatively limited. The company primarily operates in North America, which exposes it to potential market saturation and barriers to international growth. Expanding into new markets and regions would help Insulet Corp diversify its customer base and decrease its dependence on a single market.
Opportunities
The global diabetic population is on the rise, creating a significant opportunity for Insulet Corp. As more individuals require insulin delivery systems, the demand for the company's innovative technology is expected to increase. Insulet Corp can capitalize on this growing market by expanding its product offerings and marketing efforts to reach a larger customer base.
The rapid advancements in connected devices and the Internet of Things (IoT) present an opportunity for Insulet Corp to enhance its insulin delivery system. By incorporating connectivity features and leveraging data analytics, the company can provide more personalized and effective solutions for diabetic patients. This would not only improve patient experience but also drive customer loyalty and market differentiation.
Insulet Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Insulet Segments
Insulet Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
Insulet Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
Insulet Revenue by Region
3 Years
5 Years
Max
Details
Insulet Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Insulet historical P/E ratio, EBIT multiple, and P/S ratio
Insulet annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Insulet's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Insulet's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Insulet's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Insulet shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Insulet forecasts and price targets in September 2026
Analyst Price Targets 2026Insulet Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/6/2026 | Downgrade | OverweightEqual Weight | 58 | |
| 8/6/2026 | Maintained | Neutral | 49 | |
| 8/6/2026 | Downgrade | BuyHold | – | |
| 8/6/2026 | Maintained | Hold | 58 | |
| 8/6/2026 | Maintained | Buy | 57 | |
| 8/6/2026 | Maintained | Outperform | 48 | |
| 8/6/2026 | Downgrade | OutperformMarket Perform | – | |
| 8/6/2026 | Downgrade | OverweightNeutral | 53 | |
| 8/6/2026 | Maintained | Buy | 63 | |
| 8/6/2026 | Downgrade | BuyNeutral | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Insulet Earnings Calls
Insulet Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/5/2026 | 1.47USD | - | 802.84 MUSD | - | 2026 Q2 |
| 5/6/2026 | 1.22USD | - | 742.92 MUSD | - | 2026 Q1 |
| 2/18/2026 | 1.48USD | - | 784.07 MUSD | - | 2025 Q4 |
| 11/7/2024 | 0.77USD | - | 528.62 MUSD | - | 2024 Q3 |
| 5/2/2024 | 0.45USD | - | 451.34 MUSD | - | 2024 Q1 |
| 2/21/2024 | 0.67USD | - | 469.69 MUSD | - | 2023 Q4 |
| 8/2/2023 | 0.23USD | - | 355.72 MUSD | - | 2023 Q2 |
| 5/3/2023 | 0.17USD | - | 338.84 MUSD | - | 2023 Q1 |
| 2/21/2023 | 0.23USD | - | 335.82 MUSD | - | 2022 Q4 |
| 11/3/2022 | 0.15USD | 0.35USD | 317.07 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Insulet stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Insulet shareholder structure
| % | Name |
|---|---|
12.05852% | |
8.86952% | |
7.87693% | |
6.37019% | |
6.15645% | |
6.13328% |
Insulet Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.48% | SEC ↗ | |
11.00% | SEC ↗ | |
10.70% | SEC ↗ | |
9.98% | SEC ↗ | |
9.34% | SEC ↗ | |
8.21% | SEC ↗ | |
8.10% | SEC ↗ | |
8.10% | SEC ↗ | |
8.10% | SEC ↗ | |
8.10% | SEC ↗ |
Insulet Executives and Management Board
19 members · avg. age 55 · 42 % women
Mr. Eric Benjamin (42)
Chief Operating Officer
4.14 M USD
Management
Mr. John Kapples (65)
Senior Vice President, General Counsel
Mr. Dan Manea (58)
Chief Human Resources Officer, Senior Vice President
Ms. Lauren Budden (49)
Chief Accounting Officer, Group Vice President, Corporate Controller
Ms. Flavia Pease (52)
Chief Financial Officer, Executive Vice President · since 2024
Ms. Ashley Mcevoy (54)
President, Chief Executive Officer, Director · since 2025
Ms. Laetitia Cousin (49)
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
Board of Directors
Mr. Timothy Scannell (60)
Independent Chairman of the Board
Ms. Elizabeth Weatherman (65)
Independent Director
Dr. Wayne Frederick (53)
Independent Director
Mr. Michael Minogue (58)
Independent Director
Dr. Luciana Borio (54)
Independent Director
Dr. Jessica Hopfield (60)
Independent Director
Insulet Supply Chain
Insulet Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.61 | 0.34 | 0.64 | ||
| 2 | 0.84 | 0.83 | 0.55 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.18 | -0.49 | -0.44 | ||
| 2 | 0.16 | -0.30 | -0.31 |
Frequently asked questions about Insulet
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analysts currently set an average price target of 363.98 USD for the Insulet stock (median: 367.20 USD), implying +175.5 % versus the latest price. The consensus is based on 34 analyst ratings.
34 analysts currently rate the Insulet stock: 31 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Insulet to generate revenue of 3.29 B USD and earnings per share of 6.62 USD.
Converted at the current exchange rate, the Insulet share trades at 114.37 EUR (132.12 USD).
The Insulet share (PODD) is listed on 5 stock exchanges, including: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
The expected revenue of Insulet is 3.29 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Insulet is 467.48 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Insulet is currently 19.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Insulet stock.
The price-to-sales ratio (P/S) of Insulet is currently 2.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Insulet stock.
The Eulerpool Quality Score for Insulet is 6/10.
The ISIN of Insulet is US45784P1012. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Insulet is A0MQX8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Insulet is PODD. The ticker symbol is used to trade Insulet shares on the stock exchange.
Insulet paid dividends every year for the past 0 years.
Insulet is assigned to the 'Health' sector.
The dividends of Insulet are distributed in USD.
Insulet stock
Insulet Peer Group
Insulet Ticker
Insulet FIGI
All fundamentals and in-depth analysis of Insulet
Our stock analysis for Insulet stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insulet. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.